Literature DB >> 1627806

Failure to detect evidence of human T-lymphotropic virus (HTLV) type I and type II in blood donors with isolated gag antibodies to HTLV-I/II.

R B Lal1, D L Rudolph, J E Coligan, S K Brodine, C R Roberts.   

Abstract

Of the 267,650 blood donations from members of the US armed forces, 72 (0.027%) were serologically confirmed to be positive for human T-lymphotropic virus type I/II (HTLVpos) and 379 (0.14%) were Western blot (WB)-indeterminate with banding pattern restricted to the proteins encoded by the gag gene only (HTLVind). To determine whether these apparently healthy HTLVind blood donors are infected with HTLV-I or HTLV-II, coded specimens from randomly selected military blood donors (n = 73) were tested for antibodies to HTLV by WB and radioimmunoprecipitation assay (RIPA) using HTLV-I (MT-2) antigens, by enzyme immunoassay using synthetic peptides representing the immunodominant epitopes of HTLV, and for sequences of proviral HTLV DNA by the polymerase chain reaction (PCR). Of the 73 HTLVind donors, none showed presence of env reactivity by HTLV WB and RIPA. Minimal reactivity was observed with synthetic immunodominant motifs derived from the env protein of HTLV-I (Env-1(191-214) and Env-5(242-257)) or HTLV-II (Env-2(187-209) and Env-20(85-102)) and gag protein (Gag-1a(102-117) and Gag-10(364-385)). A peptide corresponding to the endogenous retroviral sequence with structural homologies to the gag protein of HTLVs (RTVLgag) reacted with antibodies not only in HTLVpos (88%) and HTLVind (42% to 66%) specimens, but also reacted with normal control subjects (60%). Furthermore, none of the 73 HTLVind specimens demonstrated presence of the HTLV genome when amplified with primers for the pol and tax/rex region. Six to 23 months from the initial test, 27 subjects still gave indeterminate WB patterns, and 13 of these repeat specimens were still negative for the presence of HTLV genome. We conclude that individuals at low risk for HTLV infection who have HTLVind WB reactivity are rarely, if ever, infected with HTLV-I or HTLV-II.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627806

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk.

Authors:  F J Medrano; V Soriano; E J Calderón; C Rey; M Gutiérrez; R Bravo; M Leal; J González-Lahoz; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

2.  Detection of human T-lymphotropic virus (HTLV) tax sequences in New York City blood donors seronegative for HTLV types 1 and 2.

Authors:  Charlene S Dezzutti; Patricia C Guenthner; Sylvester Daniel; Ursula Utz; Thania Cabrera; James H Marshall; Celso Bianco; Renu B Lal; Elliot P Cowan
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

3.  Characterization and sequencing of prototypic human T-lymphotropic virus type 1 (HTLV-1) from an HTLV-1/2 seroindeterminate patient.

Authors:  A Waziri; S S Soldan; M D Graf; J Nagle; S Jacobson
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Assessment of a new immunoassay for serological confirmation and discrimination of human T-cell lymphotropic virus infections.

Authors:  M Zrein; J Louwagie; H Boeykens; L Govers; G Hendrickx; F Bosman; E Sablon; C Demarquilly; M Boniface; E Saman
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

5.  Human T-cell lymphotropic virus type 1 gag indeterminate western blot patterns in Central Africa: relationship to Plasmodium falciparum infection.

Authors:  R Mahieux; P Horal; P Mauclère; O Mercereau-Puijalon; M Guillotte; L Meertens; E Murphy; A Gessain
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

6.  Serological, epidemiological, and molecular differences between human T-cell lymphotropic virus Type 1 (HTLV-1)-seropositive healthy carriers and persons with HTLV-I Gag indeterminate Western blot patterns from the Caribbean.

Authors:  F Rouet; L Meertens; G Courouble; C Herrmann-Storck; R Pabingui; B Chancerel; A Abid; M Strobel; P Mauclere; A Gessain
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

7.  Enhanced specificity of truncated transmembrane protein for serologic confirmation of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infections by western blot (immunoblot) assay containing recombinant envelope glycoproteins.

Authors:  M Varma; D L Rudolph; M Knuchel; W M Switzer; K G Hadlock; M Velligan; L Chan; S K Foung; R B Lal
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

8.  Isolation, characterization, and transmission of human T-lymphotropic virus types I and II in culture.

Authors:  K Kitamura; D L Rudolph; C Goldsmith; T M Folks; R B Lal
Journal:  Curr Microbiol       Date:  1993-12       Impact factor: 2.188

9.  Immunologic cross-reactivity between structural proteins of human T-cell lymphotropic virus type I and the blood stage of Plasmodium falciparum.

Authors:  R B Lal; D Rudolph; M P Alpers; A J Sulzer; Y P Shi; A A Lal
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

Review 10.  The prevalence and significance of HTLV-I/II seroindeterminate Western blot patterns.

Authors:  Anna Abrams; Yoshimi Akahata; Steven Jacobson
Journal:  Viruses       Date:  2011-08-02       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.